Silexion Therapeutics Regains Nasdaq Compliance
Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company, has recently announced a significant milestone. The firm, recognized for its innovative RNA interference (RNAi) therapies targeting KRAS-driven cancers, has regained compliance with the Nasdaq listing requirements. This achievement follows a written confirmation from Nasdaq detailing compliance with the minimum bid price and shareholders' equity standards.
Meeting Nasdaq Requirements
According to Nasdaq's letter, Silexion has satisfied the critical minimum bid price requirement of $1.00 per share, alongside the $2.5 million minimum shareholders' equity necessity. This compliance allows Silexion to maintain its presence on the Nasdaq Capital Market, continuing its commitment to advancing oncology therapeutics.
CEO's Statement on the Achievement
Ilan Hadar, Chairman and CEO of Silexion Therapeutics, expressed excitement over the regained compliance. He noted, "We are pleased to have regained full compliance with Nasdaq's listing requirements. This accomplishment highlights our sound financial foundation as we progress towards the upcoming Phase 2/3 clinical trials for our lead candidate, SIL204, which is scheduled to begin in the near future."
Advancing Clinical Trials
Silexion is preparing for its Phase 2/3 clinical trials for SIL204, expected to offer transformative solutions for patients afflicted by KRAS-driven cancers. With recent preclinical results showcasing remarkable inhibition rates of up to 97%, the company is optimistically pursuing its innovative agenda.
About Silexion Therapeutics
As a pioneering entity in biotechnology, Silexion Therapeutics focuses on developing cutting-edge treatments for solid tumor cancers tied to the mutated KRAS oncogene. This oncogene, widely recognized as a major driver in various cancers, has propelled Silexion to conduct noteworthy clinical trials. One such study evaluating its first-generation product demonstrated positive trends compared to traditional chemotherapy, reinforcing its goal of advancing oncology treatment.
Innovations in Oncology
Silexion is dedicated to advancing therapeutic practices, particularly for hard-to-treat cancers like pancreatic cancer. The company's leadership believes in the potential of RNAi therapies to redefine treatment options, and it is actively collaborating with strategic contract research organizations (CROs) to enhance its clinical development.
Conclusion
Regaining compliance with Nasdaq listing requirements serves as a key pillar in Silexion's journey towards developing groundbreaking treatments. By staying resilient and committed to its mission, Silexion Therapeutics is poised to make substantial contributions to oncology therapeutics, improving outcomes for patients facing challenging cancer diagnoses.
Frequently Asked Questions
What is Silexion Therapeutics known for?
Silexion Therapeutics specializes in creating RNA interference (RNAi) therapies targeting KRAS-driven cancers.
What significant milestone did Silexion recently achieve?
The company regained compliance with Nasdaq listing requirements for bid price and shareholders' equity.
Who is the CEO of Silexion Therapeutics?
Ilan Hadar is the Chairman and CEO, guiding the company's strategic direction and clinical trials.
What are the company's clinical development plans?
Silexion plans to initiate Phase 2/3 clinical trials for its lead product, SIL204, aimed at treating KRAS-driven cancers.
How does Silexion plan to enhance its clinical development?
The company is collaborating with strategic CRO partners to facilitate its clinical research and development efforts.
